comparemela.com

Latest Breaking News On - Cetuximab - Page 1 : comparemela.com

Dr Lenz on the Prognostic Value of HER2 Expression in mCRC

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.

Heinz-josef-lenz
Gastrointestinal-gi-oncology-program
Clinical-research
University-of-southern-california
Department-of-preventive-medicine
Norris-comprehensive-cancer-center
Department-of-medicine
Division-of-oncology
Keck-school-of-medicine
Colorectal-center
Oncology-program

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Texas
United-states
Houston
San-diego
California
American
Daiichi-sankyo
Bristol-meyers-squibb
Redx-pharma
Eli-lilly
Navire-pharma
Genentech-roche

Cetuximab Effective in Patients With CRC After Induction Chemotherapy

A study found that cetuximab along or with chemotherapy was an effective option in patients with metastatic colorectal cancer (CRC).

Qilu-hospital-in-shandong-university
Cancer-management
Qilu-hospital
Crc
Cetuximab
Chemotherapy

FDA Grants Priority Review to Adagrasib/Cetuximab Combination Therapy in KRAS G12C–Mutant CRC

A sNDA for adagrasib plus cetuximab in advanced KRAS G12C–mutated colorectal cancer was granted priority review by the FDA.

Bristol-myers-squibb
Anne-kerber
Bristol-meyers-squibb
Drug-administration
Prescription-drug-user-fee-act
Cell-therapy
Colorectal-cancer
Crc
Mss-crc
Fda
Fast-track-designation
Adagrasib

Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRC

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Iman-imanirad
Moffitt-cancer-center
Cetuximab
Encorafenib
Raf-v600e-metastatic-colorectal-cancer-
Beacon-crc
Toxicities
Prophylaxis

vimarsana © 2020. All Rights Reserved.